Overview

APL-102 Capsule in Patients With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of APL-102 Capsule and characterize the pharmacokinetic (PK) profile in advanced solid tumor patients.
Phase:
Phase 1
Details
Lead Sponsor:
Apollomics Inc.
Collaborator:
Zhejiang CrownMab Biotech Co. Ltd